Previously unpublished clinical data support the potential long‑term safety and efficacy of collagenase clostridium histolyticum (CCH) for plantar fibromatosis. The findings will be presented at the ...
Plantar fibromatosis is a progressive condition with no FDA-approved nonsurgical treatment options. With no official treatment guidelines available, Keenova and its clinical partners are working to ...
MALVERN, Pa., July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during ...
Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced results from its Phase 2 ...
Plantar fibromatosis is a progressive condition with no FDA-approved nonsurgical treatment options. Keenova is investigating collagenase clostridium histolyticum (CCH) as a potential therapy. CCH is ...
Plantar fibromatosis is a rare condition, and most newly diagnosed patients receive conservative (nonsurgical) treatments. Real-world treatment patterns suggest symptoms may persist or return, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results